Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 151 to 175 of 325

Guidance and quality standards awaiting development
Title	Type
Managing symptoms with an uncertain cause	Quality standard
Masitinib with riluzole for treating amyotrophic lateral sclerosis TS ID 10728	Technology appraisal guidance
Mavorixafor for treating WHIM syndrome ID3946	Technology appraisal guidance
Mepolizumab for reducing eosinophilic exacerbations of chronic obstructive pulmonary disease [ID1237]	Technology appraisal guidance
MIM8 for preventing bleeding episodes in haemophilia A in people 1 year and over ID6400	Technology appraisal guidance
Mirabegron for treating neurogenic detrusor overactivity in people aged 3 to 17 TS ID 10730	Technology appraisal guidance
Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer ID6442	Technology appraisal guidance
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]	Technology appraisal guidance
Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over TS ID 11777	Technology appraisal guidance
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]	Technology appraisal guidance
Neuro-Cells stem-cell treatment for traumatic spinal cord injury [TS ID 12048]	Technology appraisal guidance
Nicardipine (Nicaplant) for aneurysmal subarachnoid haemorrhage patients undergoing aneurysm clipping TS ID 10593	Technology appraisal guidance
Nipocalimab for treating generalised myasthenia gravis TS ID 11958	Technology appraisal guidance
Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer TSID 12044	Technology appraisal guidance
Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer TS ID 10523	Technology appraisal guidance
Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316]	Technology appraisal guidance
Niraparib with pembrolizumab for maintenance treatment of advanced non-small-cell lung cancer after platinum-based chemotherapy with pembrolizumab [ID6345]	Technology appraisal guidance
Nirogacestat for treating desmoid tumours TSID 12039	Technology appraisal guidance
Nitazoxanide for treating the common cold in people 12 years and over TS ID 10548	Technology appraisal guidance
Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]	Technology appraisal guidance
Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma TS ID 9659	Technology appraisal guidance
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]	Technology appraisal guidance
Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 melanoma in people 12 years and over ID 6475	Technology appraisal guidance
Obinutuzumab for treating lupus nephritis ID 6420	Technology appraisal guidance
Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy TSID 11996	Technology appraisal guidance

Results per page

10
25
50
All